Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.74
0.00 (0.00%)
At close: Sep 8, 2026, 4:00 PM EDT
12.78
+0.04 (0.31%)
After-hours: Sep 8, 2026, 7:59 PM EDT
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $7.66M in the quarter ending June 30, 2026, a decrease of -46.23%. This brings the company's revenue in the last twelve months to $59.51M, up 12.58% year-over-year. In the year 2025, Intellia Therapeutics had annual revenue of $67.67M with 16.92% growth.
Revenue (ttm)
$59.51M
Revenue Growth
+12.58%
P/S Ratio
30.00
Revenue / Employee
$157,841
Employees
377
Market Cap
1.79B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.67M | 9.79M | 16.92% |
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Lakefront Biotherapeutics NV | 1.13B |
| Immunocore Holdings | 430.78M |
| Novavax | 413.80M |
| Syndax Pharmaceuticals | 252.25M |
| Septerna | 98.88M |
| Taysha Gene Therapies | 5.49M |
| Inhibrx Biosciences | 1.30M |
NTLA News
- 19 hours ago - Intellia Therapeutics announces FDA acceptance of lonvo-z BLA - TheFly
- 19 hours ago - Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE) - GlobeNewsWire
- 4 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 days ago - Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million - GlobeNewsWire
- 4 days ago - Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 6 days ago - Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today - TheFly
- 15 days ago - Cathie Wood’s ARK Investment buys 169K shares of Intellia Therapeutics today - TheFly
- 4 weeks ago - Intellia Therapeutics upgraded to Outperform from In Line at Evercore ISI - TheFly